0001209191-20-054825.txt : 20201014 0001209191-20-054825.hdr.sgml : 20201014 20201014180015 ACCESSION NUMBER: 0001209191-20-054825 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201013 FILED AS OF DATE: 20201014 DATE AS OF CHANGE: 20201014 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Primiano Christopher Brett CENTRAL INDEX KEY: 0001603510 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36167 FILM NUMBER: 201239859 MAIL ADDRESS: STREET 1: C/O KARYOPHARM THERAPEUTICS INC. STREET 2: 85 WELLS AVENUE, SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Karyopharm Therapeutics Inc. CENTRAL INDEX KEY: 0001503802 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263931704 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 85 WELLS AVENUE STREET 2: SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 BUSINESS PHONE: 617-658-0600 MAIL ADDRESS: STREET 1: 85 WELLS AVENUE STREET 2: SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-10-13 0 0001503802 Karyopharm Therapeutics Inc. KPTI 0001603510 Primiano Christopher Brett C/O KARYOPHARM THERAPEUTICS INC. 85 WELLS AVENUE NEWTON MA 02459 0 1 0 0 EVP, CBO, GC & Secretary Common Stock 2020-10-13 4 M 0 38550 9.21 A 43199 D Common Stock 2020-10-13 4 S 0 38550 16.85 D 4649 D Common Stock 2020-10-13 4 M 0 721 10.39 A 5370 D Common Stock 2020-10-13 4 S 0 721 17.20 D 4649 D Stock Option (right to buy) 9.21 2020-10-13 4 M 0 38550 0.00 D 2029-02-14 Common Stock 38550 64250 D Stock Option (right to buy) 10.39 2020-10-13 4 M 0 721 0.00 D 2027-01-19 Common Stock 721 75779 D These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on February 15, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter. This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter. /s/ Christopher B. Primiano 2020-10-14